Ignite Creation Date:
2025-12-24 @ 9:45 PM
Ignite Modification Date:
2025-12-28 @ 4:27 PM
Study NCT ID:
NCT05853432
Status:
COMPLETED
Last Update Posted:
2023-05-10
First Post:
2023-05-02
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Descriptive Study of Baseline Characteristics, Clinical Outcomes, and Treatment Patterns of HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Alpelisib Plus Fulvestrant Who Have Received Fulvestrant in Any Prior Line of Therapy
Sponsor:
Novartis Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-03-16
Start Date Type:
ACTUAL
Primary Completion Date:
2022-05-02
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-05-02
Completion Date Type:
ACTUAL
First Submit Date:
2023-05-02
First Submit QC Date:
None
Study First Post Date:
2023-05-10
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-05-02
Last Update Post Date:
2023-05-10
Last Update Post Date Type:
ACTUAL